PGNY:NSD-Progyny Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 27

Change

0.00 (0.00)%

Market Cap

USD 2.62B

Volume

1.06M

Analyst Target

USD 34.67
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-26 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
GEHC GE HealthCare Technologies Inc..

N/A

USD 34.92B
HQY HealthEquity Inc

N/A

USD 7.42B
RCM R1 RCM Inc

N/A

USD 5.34B
GDRX Goodrx Holdings Inc

N/A

USD 3.17B
CERT Certara Inc

N/A

USD 2.79B
TXG 10X Genomics Inc

N/A

USD 2.62B
PRVA Privia Health Group Inc

N/A

USD 2.05B
PINC Premier Inc

N/A

USD 1.97B
BTSG BrightSpring Health Services I..

N/A

USD 1.92B
SDGR Schrodinger Inc

N/A

USD 1.58B

ETFs Containing PGNY

EDOC:AU BetaShares Digital Health.. 3.35 % 0.00 %

N/A

N/A
JSML Janus Henderson Small Cap.. 2.30 % 0.50 %

N/A

USD 0.22B

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -27.38% 31% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.38% 31% F 21% F
Trailing 12 Months  
Capital Gain -27.79% 59% D- 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.79% 57% F 28% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 19.74% 84% B 79% B-
Dividend Return 19.74% 83% B 78% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 55.56% 25% F 30% F
Risk Adjusted Return 35.53% 89% A- 69% C-
Market Capitalization 2.62B 88% B+ 83% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.